NASDAQ:XBIT XBiotech (XBIT) Stock Price, News & Analysis $2.66 -0.01 (-0.37%) Closing price 06/25/2025 04:00 PM EasternExtended Trading$2.67 +0.01 (+0.38%) As of 04:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About XBiotech Stock (NASDAQ:XBIT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get XBiotech alerts:Sign Up Key Stats Today's Range$2.58▼$2.7750-Day Range$2.50▼$3.1652-Week Range$2.50▼$8.32Volume74,953 shsAverage Volume69,207 shsMarket Capitalization$81.10 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewXBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.Read More… XBiotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks10th Percentile Overall ScoreXBIT MarketRank™: XBiotech scored higher than 10% of companies evaluated by MarketBeat, and ranked 904th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for XBiotech. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of XBiotech is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of XBiotech is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXBiotech has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about XBiotech's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.98% of the float of XBiotech has been sold short.Short Interest Ratio / Days to CoverXBiotech has a short interest ratio ("days to cover") of 15.1, which indicates bearish sentiment.Change versus previous monthShort interest in XBiotech has recently decreased by 3.80%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXBiotech does not currently pay a dividend.Dividend GrowthXBiotech does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.98% of the float of XBiotech has been sold short.Short Interest Ratio / Days to CoverXBiotech has a short interest ratio ("days to cover") of 15.1, which indicates bearish sentiment.Change versus previous monthShort interest in XBiotech has recently decreased by 3.80%, indicating that investor sentiment is improving. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for XBiotech this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added XBiotech to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, XBiotech insiders have not sold or bought any company stock.Percentage Held by Insiders33.10% of the stock of XBiotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.70% of the stock of XBiotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about XBiotech's insider trading history. Receive XBIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter. Email Address XBIT Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBITFebruary 4, 2025 | prnewswire.comXBiotech stock hits 52-week low at $3.5 amid market challengesJanuary 28, 2025 | msn.comA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself.June 26 at 2:00 AM | American Alternative (Ad)XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law FirmJanuary 17, 2025 | prnewswire.comWolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities lawsJanuary 14, 2025 | globenewswire.comXBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law FirmJanuary 13, 2025 | businesswire.comXBiotech Inc.'s (NASDAQ:XBIT) largest shareholders are individual investors with 49% ownership, insiders own 35%January 10, 2025 | finance.yahoo.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBITJanuary 8, 2025 | prnewswire.comSee More Headlines XBIT Stock Analysis - Frequently Asked Questions How have XBIT shares performed this year? XBiotech's stock was trading at $3.95 on January 1st, 2025. Since then, XBIT stock has decreased by 32.7% and is now trading at $2.66. View the best growth stocks for 2025 here. How were XBiotech's earnings last quarter? XBiotech Inc. (NASDAQ:XBIT) released its quarterly earnings results on Wednesday, May, 14th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter. When did XBiotech IPO? XBiotech (XBIT) raised $76 million in an IPO on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co acted as the underwriter for the IPO. Who are XBiotech's major shareholders? Top institutional shareholders of XBiotech include American Century Companies Inc. (0.33%), Charles Schwab Investment Management Inc. (0.22%), Connor Clark & Lunn Investment Management Ltd. (0.21%) and Goldman Sachs Group Inc. (0.15%). View institutional ownership trends. How do I buy shares of XBiotech? Shares of XBIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of XBiotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that XBiotech investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and AU Optronics (AUOTY). Company Calendar Last Earnings5/14/2025Today6/26/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XBIT CIK1626878 Webwww.xbiotech.com Phone(512) 386-2900Fax512-386-5505Employees100Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.53 million Net MarginsN/A Pretax MarginN/A Return on Equity-21.14% Return on Assets-19.55% Debt Debt-to-Equity RatioN/A Current Ratio29.15 Quick Ratio29.15 Sales & Book Value Annual Sales$4.01 million Price / Sales20.23 Cash FlowN/A Price / Cash FlowN/A Book Value$5.98 per share Price / Book0.44Miscellaneous Outstanding Shares30,490,000Free Float20,396,000Market Cap$81.10 million OptionableOptionable Beta0.97 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:XBIT) was last updated on 6/26/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTop Picks for Trump’s Pro-Crypto America27 of crypto's most successful minds are about to pull back the curtain… Bitcoin has crushed its all-time h...Crypto 101 Media | SponsoredWar Tensions Are Making Gold Rise to Record HighsIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Recession Already Started, Are You Prepared?Global central banks are stockpiling gold. Billionaires are hedging with precious metals. And thousands of Ame...Lear Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XBiotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share XBiotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.